NASDAQ:ASND - Ascendis Pharma A/S Stock Price, Forecast & News

Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND."

Ascendis Pharma A/S (NASDAQ:ASND) issued its quarterly earnings data on Tuesday, May, 23rd. The biotechnology company reported ($0.83) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.64) by $0.19. The biotechnology company earned $0.40 million during the quarter, compared to the consensus estimate of $1.10 million. Ascendis Pharma A/S had a negative return on equity of 29.04% and a negative net margin of 789.80%. View Ascendis Pharma A/S's Earnings History.

Ascendis Pharma A/S is scheduled to release their next quarterly earnings announcement on Wednesday, April 1st 2020. View Earnings Estimates for Ascendis Pharma A/S.

8 analysts have issued twelve-month price targets for Ascendis Pharma A/S's stock. Their forecasts range from $139.00 to $186.00. On average, they anticipate Ascendis Pharma A/S's stock price to reach $158.00 in the next twelve months. This suggests a possible upside of 8.9% from the stock's current price. View Analyst Price Targets for Ascendis Pharma A/S.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ascendis Pharma A/S.

Press coverage about ASND stock has trended extremely negative this week, InfoTrie reports. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ascendis Pharma A/S earned a coverage optimism score of -4.3 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Ascendis Pharma A/S.

Ascendis Pharma A/S saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 2,430,000 shares, an increase of 12.5% from the January 15th total of 2,160,000 shares. Based on an average daily volume of 250,000 shares, the days-to-cover ratio is presently 9.7 days. Currently, 5.5% of the shares of the stock are sold short. View Ascendis Pharma A/S's Current Options Chain.

Some companies that are related to Ascendis Pharma A/S include Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), UCB (UCBJF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Teva Pharmaceutical Industries (TEVA), Elanco Animal Health (ELAN), Mylan (MYL), Beigene (BGNE), Bausch Health Companies (BHC) and Ono Pharmaceutical (OPHLF).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ascendis Pharma A/S investors own include AbbVie (ABBV), Neurocrine Biosciences (NBIX), Exelixis (EXEL), Merck & Co., Inc. (MRK), Teva Pharmaceutical Industries (TEVA), ACADIA Pharmaceuticals (ACAD), Alexion Pharmaceuticals (ALXN), Amarin (AMRN), BioMarin Pharmaceutical (BMRN) and Gilead Sciences (GILD).

(ASND) raised $85 million in an initial public offering on Wednesday, January 28th 2015. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and Wells Fargo Securities was co-manager.

Ascendis Pharma A/S's stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (11.33%), RA Capital Management L.P. (9.93%), Artisan Partners Limited Partnership (5.12%), Farallon Capital Management LLC (3.04%), Westfield Capital Management Co. LP (2.99%) and Janus Henderson Group PLC (2.62%).

ASND stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Farallon Capital Management LLC, Franklin Resources Inc., Renaissance Technologies LLC, Lakewood Capital Management LP, Schonfeld Strategic Advisors LLC, Goldman Sachs Group Inc. and FIL Ltd.

ASND stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Westfield Capital Management Co. LP, Bank of New York Mellon Corp, Spyglass Capital Management LLC, Victory Capital Management Inc., Victory Capital Management Inc., State Street Corp and RA Capital Management L.P..

Shares of ASND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ASND stock can currently be purchased for approximately $145.11.

Ascendis Pharma A/S has a market capitalization of $6.93 billion and generates $12.50 million in revenue each year. The biotechnology company earns $-153,650,000.00 in net income (profit) each year or ($3.74) on an earnings per share basis. Ascendis Pharma A/S employs 216 workers across the globe.View Additional Information About Ascendis Pharma A/S.

The official website for Ascendis Pharma A/S is http://www.ascendispharma.com/.

Ascendis Pharma A/S's mailing address is TUBORG BOULEVARD 12, HELLERUP G7, DK-2900. The biotechnology company can be reached via phone at 45-7022-2244 or via email at [email protected]